ANTIBODIES FOR THE PREVENTION OR THE TREATMENT OF BLEEDING EPISODES

摘要

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).

主权项

1. An isolated monoclonal antibody that specifically binds to the D4 domain of human von Willebrand factor (VWF), competes for binding to VWF D4 domain with A Disintegrin And Metalloprotease with ThromboSpondin domains-13 (ADAMTS13) and inhibits between 50 and 80% of ADAMTS13-mediated degradation of high molecular weight (HMW)-multimers of VWF.